<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01341067</url>
  </required_header>
  <id_info>
    <org_study_id>RMDC-001</org_study_id>
    <nct_id>NCT01341067</nct_id>
  </id_info>
  <brief_title>Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes</brief_title>
  <acronym>DexlonT2</acronym>
  <official_title>Continuous Glucose Monitoring in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rocky Mountain Diabetes and Osteoporosis Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rocky Mountain Diabetes and Osteoporosis Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effect CGM (continuous glucose monitoring) has on
      subjects with type 2 diabetes. It is anticipated that patients using the device will obtain
      tighter control of their blood sugars resulting in measureable health benefits and improved
      confidence in their ability to manage their diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HgbA1c</measure>
    <time_frame>Measured at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Spent at Glycemic Levels &lt;65 mg/dl</measure>
    <time_frame>Measured at baseline and at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage of Time Spent at Glycemic Levels &gt;180 mg/dl</measure>
    <time_frame>Measured at baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Basal Insulin Dose From Baseline Values</measure>
    <time_frame>Assessed at baseline and 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Basal insulin, approved oral medications</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects of all adult ages (18 and older) with type 2 diabetes.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have been diagnosed with type 2 diabetes mellitus

          -  Have an HgbA1c value ≥ 7% and ≤17%.

          -  Are on basal insulin, with or without oral agents

          -  Are not on basal bolus insulin therapy.

          -  Have had no severe hypoglycemic episodes in the 6 months prior to enrollment in the
             study. Severe hypoglycemia will be defined as any hypoglycemia that is both
             neurologically impairing and absolutely requires assistance from a third party in the
             form of carbohydrates, glucagon shots, or attention from a paramedic or other
             healthcare professional.

          -  Have no known allergy to medical tape or sensors.

          -  Are capable of and willing to test their blood glucose (BG) on an average of 4 times
             per day.

          -  Are willing to not use Acetaminophen while enrolled in the study.

          -  Are willing not to undergo a MRI procedure while wearing the CGM sensor.

          -  Are willing and capable of performing self insertions of the device sensor.

          -  Women of child bearing potential must be willing to use an approved form of birth
             control while enrolled in the study.

          -  Women of child bearing potential must be willing to perform pregnancy tests monthly
             while enrolled in the study.

          -  Can understand and speak English fluently.

        Exclusion Criteria

          -  Have been on pump therapy in the 6 months prior to enrollment in the study.

          -  Are receiving basal- bolus insulin therapy

          -  Are taking any medication that is not approved to be taken with insulin.

          -  Are pregnant or have intentions of becoming pregnant during the duration of the study.

          -  Have any skin condition that would inhibit the proper wearing of the CGM sensor
             including severe psoriasis, burns, eczema, scarring, excessive tattoos, etc.

          -  Have a hematocrit ≤30% or ≥55%

          -  Are currently enrolled in another clinical study (subjects must have ended
             participation in other studies at least 30 days prior to enrolling in this study.

          -  Are employed by any company that manufactures or is developing a CGM device.

          -  Are deemed incapable of participating in the study by the Primary Investigator for any
             reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R. Liljenquist, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rocky Mountain Diabetes and Osteoporosis Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes and Osteoporosis Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>April 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2011</study_first_posted>
  <results_first_submitted>March 22, 2013</results_first_submitted>
  <results_first_submitted_qc>April 1, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 2, 2014</results_first_posted>
  <last_update_submitted>April 1, 2014</last_update_submitted>
  <last_update_submitted_qc>April 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rocky Mountain Diabetes and Osteoporosis Center</investigator_affiliation>
    <investigator_full_name>David Liljenquist, M.D.</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Basal Insulin, Approved Oral Medications</title>
          <description>Basal insulin, with or without approved oral agents</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Basal Insulin, Approved Oral Medications</title>
          <description>Basal insulin, with or without approved oral agents</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HgbA1c</title>
        <time_frame>Measured at 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Insulin, Approved Oral Medications</title>
            <description>Basal insulin, with or without approved oral agents</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HgbA1c</title>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="1.1" lower_limit="-3.0" upper_limit="-.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Spent at Glycemic Levels &lt;65 mg/dl</title>
        <time_frame>Measured at baseline and at 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Insulin, Approved Oral Medications</title>
            <description>Basal insulin, with or without approved oral agents</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent at Glycemic Levels &lt;65 mg/dl</title>
          <units>percentage of time spent &lt; 65 mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".04" spread="1.0" lower_limit="-.6" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage of Time Spent at Glycemic Levels &gt;180 mg/dl</title>
        <time_frame>Measured at baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Insulin, Approved Oral Medications</title>
            <description>Basal insulin, with or without approved oral agents</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Time Spent at Glycemic Levels &gt;180 mg/dl</title>
          <units>percentage of time spent &gt;180 mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Basal Insulin Dose From Baseline Values</title>
        <time_frame>Assessed at baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Insulin, Approved Oral Medications</title>
            <description>Basal insulin, with or without approved oral agents</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Basal Insulin Dose From Baseline Values</title>
          <units>units of insulin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>0 serious adverse events were recorded. 3 device related adverse events were recorded.</desc>
      <group_list>
        <group group_id="E1">
          <title>Basal Insulin, Approved Oral Medications</title>
          <description>Basal insulin, with or without approved oral agents</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Insertion site irritation</sub_title>
                <description>Includes mild irritation at the site of insertion that has been deemed to be device related by the Primary Investigator.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Sulik, PharmD CCRP</name_or_title>
      <organization>Rocky Mountain Diabetes and Osteoporosis Center</organization>
      <phone>208-528-9642</phone>
      <email>mark@idahomed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

